Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  Five Prime Therapeutics Inc    FPRX

FIVE PRIME THERAPEUTICS INC (FPRX)
My previous session
Most popular
  Report  
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsofficial PublicationsSector newsTweets

Five Prime Therapeutics Presents Poster on FGFR2b Expression and Immune Signature in Urothelial Cancer at the Society for Immunotherapy of Cancer 32nd Annual Meeting

share with twitter share with LinkedIn share with facebook
share via e-mail
0
11/10/2017 | 06:31pm CEST

SOUTH SAN FRANCISCO, Calif., Nov. 10, 2017 (GLOBE NEWSWIRE) -- Five Prime Therapeutics, Inc. (Nasdaq:FPRX), a clinical-stage biotechnology company focused on discovering and developing innovative immuno-oncology protein therapeutics, announced today that analyses of FGFR2b expression and baseline immune signature in urothelial cancer (UC) samples were featured in a poster presentation at the Society for Immunotherapy of Cancer (SITC) 32nd Annual Meeting, being held November 8-12, 2017 in National Harbor, Maryland. A PDF of the poster, "FGFR2b Expression and Baseline Immune Signature to Guide FPA144 Development in Urothelial Cancer," will be made available on the Publications page of the Five Prime website. Five Prime is developing FPA144, an isoform-selective antibody, as a targeted immunotherapy for tumors that overexpress FGFR2b. Five Prime continues to enroll patients in the Phase 1 trial cohort evaluating FPA144 as a treatment for patients with bladder cancer whose tumors overexpress FGFR2b.

“Profiling FGFR2b expression and baseline tumor-associated immune cells could help guide our clinical development strategy for FPA144 in bladder cancer," said Kevin Baker, Ph.D., Senior Vice President, Development Sciences at Five Prime. “Previously we showed in a pre-clinical model with moderate FGFR2b expression, that FPA144 can reprogram the tumor microenvironment making it more inflammatory. In the same studies, we also showed that FPA144 and PD-1 blockade have additive anti-tumor effects.”

Five Prime evaluated FGFR2b expression in 387 archival primary early stage UC samples and previously reported that >10% had overexpression of FGFR2b by immunohistochemistry (IHC) with intensity level of at least 1+. The research team selected 32 archival UC cases with a range of FGFR2b expression (62% were FGFR2b positive) and characterized baseline immune composition in the tumor microenvironment and the relationship with FGFR2b expression to potentially guide FPA144 development in combination with other therapies.

The results from the selected cases suggest that FGFR2b is expressed in all immune subtypes of UCs, but the expression level varies. The highest level of expression is in inflamed and more proliferative UCs. The Company plans to evaluate additional archival UC tissues from patients with more advanced metastatic disease to determine if there is an association of FGFR2b expression with baseline immune signature in late-stage patient tumors.

About Five Prime
Five Prime Therapeutics, Inc. discovers and develops innovative therapeutics to improve the lives of patients with serious diseases. Five Prime's comprehensive discovery platform, which encompasses virtually every medically relevant extracellular protein, positions it to explore pathways in cancer, inflammation and their intersection in immuno-oncology, an area with significant therapeutic potential and a growing focus of the company's R&D activities. Five Prime has entered into strategic collaborations with leading global pharmaceutical companies and has promising product candidates in clinical and late preclinical development. For more information, please visit www.fiveprime.com.

Cautionary Note on Forward-looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as "may," "will," "expect," "plan," "anticipate," "estimate," "intend" and similar expressions (as well as other words or expressions referencing future events, conditions or circumstances) are intended to identify forward-looking statements. These forward-looking statements are based on Five Prime's expectations and assumptions as of the date of this press release. Each of these forward-looking statements involves risks and uncertainties. Actual results may differ materially from these forward-looking statements. Factors that may cause actual results to differ from those expressed or implied in the forward-looking statements in this press release are discussed in Five Prime's filings with the U.S. Securities and Exchange Commission, including the "Risk Factors" contained therein. Except as required by law, Five Prime assumes no obligation to update any forward-looking statements contained herein to reflect any change in expectations, even as new information becomes available.

CONTACT
Derek Cole
Investor Relations Advisory Solutions
720-785-4497
derek.cole@iradvisory.com


© GlobeNewswire 2017
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on FIVE PRIME THERAPEUTICS IN
08/09FIVE PRIME THERAPEUTICS : 2Q Earnings Snapshot
AQ
08/08FIVE PRIME THERAPEUTICS : Management's Discussion and Analysis of Financial Cond..
AQ
08/08FIVE PRIME THERAPEUTICS INC : Results of Operations and Financial Condition, Fin..
AQ
08/08FIVE PRIME THERAPEUTICS : Announces Second Quarter 2018 Financial Results
BU
08/08FIVE PRIME THERAPEUTICS INC : Five Prime Therapeutics, Inc. to Host Earnings Cal..
AC
07/26FIVE PRIME THERAPEUTICS : to Announce Second Quarter 2018 Financial Results and ..
BU
07/11Complimentary Technical Snapshots on Incyte and Three More Biotech Stocks
AC
06/11FIVE PRIME THERAPEUTICS : to Present at Goldman Sachs 39th Annual Global Healthc..
BU
06/07FIVE PRIME THERAPEUTICS : to Present at Jefferies 2018 Global Healthcare Confere..
AQ
06/07FIVE PRIME THERAPEUTICS : Walks to End Pancreatic Cancer at PurpleStride San Fra..
AQ
More news
News from SeekingAlpha
08/08Five Prime Therapeutics Inc. (FPRX) CEO Aron Knickerbocker on Q2 2018 Results.. 
08/08Five Prime Therapeutics beats by $0.30, misses on revenue 
08/08Five Prime Therapeutics, Inc. 2018 Q2 - Results - Earnings Call Slides 
07/06Biogen leads biotechs into positive territory 
06/16A High-Throughput Screen For Cancer Stocks That Have Few (Or No) Fundamentals 
Financials ($)
Sales 2018 64,3 M
EBIT 2018 -131 M
Net income 2018 -135 M
Finance 2018 96,2 M
Yield 2018 -
P/E ratio 2018 -
P/E ratio 2019
EV / Sales 2018 6,34x
EV / Sales 2019 6,84x
Capitalization 504 M
Chart FIVE PRIME THERAPEUTICS INC
Duration : Period :
Five Prime Therapeutics Inc Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends FIVE PRIME THERAPEUTICS IN
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 8
Average target price 34,6 $
Spread / Average Target 149%
EPS Revisions
Managers
NameTitle
Aron M. Knickerbocker President, Chief Executive Officer & Director
Lewis T. Williams Executive Chairman
Linda M. Rubinstein Chief Financial & Accounting Officer
Helen Collins Chief Medical Officer & Senior Vice President
Bryan Irving Chief Scientific Officer & Executive VP
Sector and Competitors
1st jan.Capitalization (M$)
FIVE PRIME THERAPEUTICS INC-37.27%504
GILEAD SCIENCES5.51%100 220
VERTEX PHARMACEUTICALS16.75%44 961
REGENERON PHARMACEUTICALS-1.11%38 873
NEUROCRINE BIOSCIENCES, INC.46.41%10 514
GENMAB2.24%9 810